AgomAb Therapeutics NV (AGMB) vs Lexeo Therapeutics (LXEO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
AgomAb Therapeutics NV is the larger company by market cap ($268.4 million vs $245.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGMB | LXEO |
|---|---|---|
| Share price | $5.45 | $2.96 |
| Market cap | $268.40M | $245.05M |
| 1-day change | -3.02% | +0.34% |
| YTD return | — | -70.19% |
| 1-year return | — | -67.33% |
| EPS (TTM) | $-2.08 | $-1.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-100.00M |
| 52-week high | $17.82 | $10.99 |
| 52-week low | $5.39 | $2.55 |
| Distance from 52-week high | -69.42% | -73.07% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +591.19% | +748.31% |
| Average volume | 208.99K | 1.98M |
| Shares outstanding | 49.25M | 82.79M |
| Employees | 62 | 68 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AgomAb Therapeutics NV
AGMB stock →AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees
About Lexeo Therapeutics
LXEO stock →Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 68 employees
AGMB vs LXEO FAQ
Which is bigger, AgomAb Therapeutics NV or Lexeo Therapeutics?
AgomAb Therapeutics NV (AGMB) is larger, with a market capitalization of $268.40M compared with $245.05M for Lexeo Therapeutics (LXEO).
Are AgomAb Therapeutics NV and Lexeo Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.